{"organizations": [], "uuid": "814d9f1475d4f53037a9f3b9266d0c3c1ff10863", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/idUSL8N1PB20N", "country": "US", "domain_rank": 408, "title": "BRIEF-MolMed: Zalmoxis Can Be Reimbursed In Germany For EUR 163,900 Per Infusion", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.988, "site_type": "news", "published": "2018-01-16T17:25:00.000+02:00", "replies_count": 0, "uuid": "814d9f1475d4f53037a9f3b9266d0c3c1ff10863"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/idUSL8N1PB20N", "ord_in_thread": 0, "title": "BRIEF-MolMed: Zalmoxis Can Be Reimbursed In Germany For EUR 163,900 Per Infusion", "locations": [], "entities": {"persons": [], "locations": [{"name": "germany", "sentiment": "none"}, {"name": "germany", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - MOLECULAR MEDICINE SPA:\n* SAYS THAT AS OF JAN 15 ZALMOXIS CAN BE PRESCRIBED AND REIMBURSED IN GERMANY AT THE PRICE OF EUR 163,900 PER INFUSION\n* APPROVED DOSAGE FORESEES ONE OR MORE INFUSIONS, UP TO A MAXIMUM OF FOUR, TILL IMMUNE-RECONSTITUTION IS ACHIEVED\n* MOLMED WILL BE RESPONSIBLE FOR THE PRODUCTION AND SUPPLY OF ZALMOXIS, WHILE DOMPÉ FARMACEUTICI WILL CONDUCT ACTIVITIES AIMED AT MARKETING THE THERAPY IN GERMANY\n* DOMPÉ WILL PAY MOLMED A PURCHASE PRICE PROPORTIONAL TO THE REIMBURSED PRICE OF THE PRODUCT\nSource text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-16T17:25:00.000+02:00", "crawled": "2018-01-17T19:47:07.000+02:00", "highlightTitle": ""}